HRAS and skin neoplasm: Mutations in the Hras, Pten, Pi3k, Mdm2, Tp63, Esr, Pgr, and Her2 genes, loss of Cdkn2a, Igf, and Akt, as well as MYC phosphorylation have been identified in DMBA-induced breast, blood, and skin tumor models [53–55].